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Background: Gabapentinoid drugs (gabapentin and pregabalin) are effective in neuropathic pain, 
which has a prevalence ~7%. Concerns about increasing prescribing have implications for patient 
safety, misuse and diversion. Drug-related deaths (DRDs) have increased and toxicology often 
implicates gabapentinoids. We studied national and regional prescribing rates (2006-2016) and 
identified associated sociodemographic factors, co-prescriptions and mortality, including DRDs. 
Methods: National data from Information Service Division, NHS Scotland. Prescribing, 
sociodemographic and mortality data from Health Informatics Centre, University of Dundee. DRDs 
where gabapentinoids were implicated identified from National Records of Scotland and Tayside 
Drug Death Databases. 
Results: From 2006-2016, the number of gabapentin prescriptions in Scotland rose 4-fold (164,630 
to 694,293), and pregabalin 16-fold (27,094 to 435,490). In 2016 ‘recurrent users’ (≥3 prescriptions):  
mean age 58.1years, mostly females (62.5%) and more likely to live in deprived areas.  60% were co-
prescribed an opioid and/or benzodiazepine (opioid 49.9%, benzodiazepine 26.8%, both 17.1%). 
Age-standardised death rate in those prescribed gabapentinoids was double the Scottish population 
(RR 2.16, 95% CI 2.08-2.25). Increases in gabapentinoids contributing to cause of DRDs were 
reported regionally and nationally (gabapentin 23% vs 15%; pregabalin 21% vs 7%). In Tayside, 
gabapentinoids were implicated in 22 (39%) DRDs, 17 (77%) of whom had not received a 
prescription. 
Conclusions: Gabapentinoid prescribing has increased dramatically since 2006, as have dangerous 
co-prescribing and death (including DRDs). Older people, women and those living in deprived areas 
were particularly likely to receive prescriptions. Their contribution to DRDs may be more related to 
illegal use, with diversion of prescribed medication. 
Keywords: data linkage, drug related deaths, gabapentinoids, mortality, prescribing
2































































Initially developed to treat epilepsy, gabapentinoid drugs (gabapentin and pregabalin) are also 
widely used in the UK for the treatment of neuropathic pain, (for which they are licenced) migraine 
and generalized anxiety disorder in adults (pregabalin only).1 
Chronic pain is common: 19% of the population in Europe were found to have chronic pain2 and 7-
10% of the population have pain with neuropathic features.3 Neuropathic pain is more severe and 
difficult to treat than non-neuropathic pain, resulting in serious detrimental impact on quality of 
life.4,5 Gabapentinoids have been shown to be effective in treating neuropathic pain and are 
indicated as first-line treatments in national and international clinical guidelines.6-8
There have been significant increases in the number of prescriptions for gabapentinoids in the past 
decade in Scotland and the UK,9-11 as well as in North America 12-14, and Europe.15 16 rief reports have 
found the rate of patients newly treated with gabapentinoids has increased 3-4 fold since 2002 9 12 
and similar increases in the number of ‘gabapentinoid-involved’ visits to a doctor have recently 
been reported.17 These increases cannot necessarily or wholly be explained by the number of cases 
of neuropathic pain or other relevant conditions. It has been suggested that clinicians, seeking 
alternatives to the prescribing of opioids18 and concerns about long term NSAID and coxib 
prescribing,19 are responding by lowering the threshold for prescribing gabapentinoids for various 
types of pain, with prescribing still increasing in England, despite reclassification as a Class C drug.20 
There have been concerns about possible misuse of gabapentinoids, often along with opioids, 
resulting in diversion and dependence issues.21,22 The co-prescribing of gabapentinoids, opioids and 
benzodiazepines is particularly concerning9 and is not unusual in patients with severe chronic pain, 
potentially putting them at high risk of overdose and dependency.23






























































Drug-related deaths are of particular public health concern currently. Prescribed gabapentinoids 
have been associated with increased risk of suicidal behaviour, as well as unintentional overdose, 
injuries, road traffic accidents and violent crime.24 In Scotland, drug-related deaths have doubled in 
the past ten years, resulting in the highest rate recorded in the EU in 2018.25   Gabapentin was 
implicated in 15.2% of these drug-related deaths and pregabalin in 16.5%. This is a substantial 
increase compared to only 3% and <1% in 2012 respectively.25 Drug-use disorders are also a major 
contributor to health inequalities as they are the greatest of cause of years lost due to ill health, 
disability or early death in the most deprived areas.26 In April 2019, gabapentin and pregabalin were 
reclassified as class C controlled substances in the UK, with greater restrictions on their prescribing 
due to concerns about their misuse and the growing number of deaths associated with the misuse of 
these drugs.27 28  Scotland is recognised as having one of the most developed recording mechanisms 
for drug-related deaths worldwide including details from death registrations, supplemented by 
toxicology information and the use of well-defined criteria.25 
In this study, we describe national and regional prescribing rates of gabapentin and pregabalin over 
an eleven-year period (2007 to 2016) and identify associated socio-demographic factors and co-
prescribing. Data from well-defined, robust datasets are examined to determine factors associated 
with co-prescribing and with drug-related deaths information.
































































National prescribing data  
The National Health Service (NHS) in Scotland is administered through 14 geographical NHS Boards. 
The Prescribing Information System (PIS) is a national individual-level dataset of prescriptions issued, 
dispensed and reimbursed within community pharmacies29 and all prescribing data are stored 
securely by the Information Services Division (ISD), part of NHS Scotland 
(http://www.isdscotland.org/). General Practitioners (GPs) account for more than 95% of community 
prescribing and capture from prescriptions is high at 98.7% for GP prescribers.29
We examined national level data from ISD. Prescribing data for two NHS Health Board regions in 
Scotland (NHS Tayside and NHS Fife) were provided by the Health Informatics Centre (HIC), 
University of Dundee (https://www.dundee.ac.uk/hic). HIC was established over 10 years ago, is 
recognised as a leader in health data linkage and maintains a clinical data repository of eHealth data, 
including prescribing. HIC combines routine collected datasets for the Tayside and Fife population 
covering approximately 20% of the Scottish population.  
Utilising both data sources, we examined: 
1. the trend in number of prescription items of gabapentin and pregabalin (2006-2016)
http://www.isdscotland.org/ (data from NHS Fife available from 2010)
2. factors associated with receiving a gabapentinoid prescription including socio-demographic
factors, co-prescribing and mortality.
3. drug-related deaths data, including those associated with gabapentin or pregabalin,
obtained from National Records of Scotland (NRS) (2007-2016)
https://www.nrscotland.gov.uk/statistics-and-data/statistics/statistics-by-theme/vital-
events/deaths/drug-related-deaths-in-scotland. The Office for National Statistics (ONS)
‘wide’ definition was used which includes all deaths coded to accidental poisoning, and to
intentional self-poisoning by drugs, medicaments and biological substances, whether or not






























































a drug listed under the Misuse of Drugs Act was present in the body.30 The use of the ‘wide’ 
definition enabled us to examine the toxicology reporting of gabapentin and pregabalin 
separately. 
Individual prescribing data from NHS Tayside & Fife
HIC conducted a prescribing linkage of all individuals who were dispensed at least one 
prescription for gabapentin or pregabalin in 2016 in NHS Tayside and NHS Fife in Scotland 
(combined population approx. 780K). This eHealth record linkage used a unique person 
identifier, the Community Health Index (CHI) number. Data were linked between the 
following datasets: prescription medicines dispensed by community pharmacies; 
demography data (age, gender, Scottish Index of Multiple Deprivation (SIMD), urban/rural 
categorisation of residence) and death records from General Records Office of Scotland 
(GROS). SIMD is based on residential postcode and grouped into quintiles, ranking those 
areas from most deprived (ranked 1) to least deprived (ranked 5). All data were pseudo-
anonymised and stored in the HIC Safe Haven for analysis. 
Prescribing data
Gabapentinoid drugs, gabapentin and pregabalin, detailed in Chapter 4.8.1 of the British 
National Formulary (BNF)1 were included. The BNF is a UK pharmaceutical reference source 
that contains guidance on prescribing, dispensing, administering and pharmacology about 
medicines available in the UK. To examine co-prescribing, we also included all opioid drugs 
(BNF Ch 4.7.2) and benzodiazepines (BNF Ch 4.1.1/4.1.2). “Recurrent users” of 
gabapentinoids were defined as those who received three or more prescriptions in the one 
year period, to exclude those patients who were prescribed a short trial of these drugs. 
Deaths






























































The age standardised mortality for patients prescribed a gabapentinoid in NHS Tayside and Fife in 
2016 was compared with Scottish national age standardised mortality data.31 The underlying cause of 
death was divided into three groups (circulatory deaths, respiratory deaths and all-cause mortality) 
to conform to the NRS categories. The standard population used to calculate age-standardised death 
rates was the 2013 European Standard Population (ESP). The ESP is a theoretical population defined 
as having a particular distribution by age, which enables comparisons between different countries or 
populations.31 
Drug-related deaths (DRDs) are identified using details from death registrations supplemented by 
toxicology information obtained from forensic pathologists and are defined as deaths (intentional or 
unintentional) due to the effect of opioids, cannabinoids, sedatives or hypnotics, cocaine (or other 
stimulants), hallucinogens or other psychoactive substances.25 Deaths that have occurred due to a 
complication of the immediate or short-term use of drugs listed above e.g. bronchopneumonia due 
to heroin intoxication, are also considered drug-related deaths. GROS data included details of the 
underlying cause of death, classified according to ICD-10 codes. Drug-related deaths are identified by 
the NRS using ICD-10 codes (see above). NRS also reports drug-related deaths using the ONS 
definition, which is wider and includes deaths coded to volatile substances and deaths not restricted 
to cases where a drug listed under the Misuse of Drugs Act (1971) was known to be present at the 
time of death.30 Given that the NRS report only presents gabapentin and pregabalin specific data for 
the ONS ‘wide’ definition, this definition has been used for the reporting of the national statistics in 
this paper.
Data from Tayside were obtained from the Tayside Drug Death Database, which informs the work of 
the Tayside Drug Death Review Group (TDDRG).32 Suspected drug deaths are notified to the Health 
Intelligence team within NHS Tayside Public Health by the Tayside Division of Police Scotland.  
Additional information is then collected from partner agencies, assimilated and subsequently 
reviewed alongside the post-mortem and toxicology findings by the TDDRG. As part of the 






























































comprehensive case review, the TDDRG determines if a case should be considered a drug death or 
not.  Drug deaths are defined by this Group as the presumed non-intentional fatal overdoses of illicit 
(or illicitly obtained controlled) substances and therefore represent a subset of drug-related deaths.
Ethical approval
Anonymised record linkage was conducted according to Health Informatics Centre (HIC), University of 
Dundee, Standard Operating Procedure (SOP) (https://www.dundee.ac.uk/hic ). The Tayside 
Research Ethics Committee does not require submission of individual studies that follow this SOP 
which is Caldicott Guardian approved.
Statistical analysis 
Mainly descriptive analyses were conducted to examine eleven-year trends (2006-2016) in 
community prescribing of gabapentinoid drugs across Scotland, NHS Tayside and NHS Fife; the 
sociodemographic characteristics of those receiving prescriptions; recurrent users of gabapentinoids, 
and prescribing of gabapentinoids along with opioids and/or benzodiazepines in 2016. Continuous 
variables are presented as mean ± SD and were analysed by independent t-test for difference in 
mean between groups.  Categorical variables are presented as counts (percentages). The associations 
of age, gender and SIMD with recurrent users of gabapentinoids in 2016, and with co-prescribing 
were examined using multivariate logistic regression and we calculated odds ratios (ORs) and 95% 
confidence intervals (CIs) for both comparisons. Relative risk and 95% CIs were calculated for each 
age standardised mortality rate. We used a threshold of 5% (p<0.05) for statistical significance in our 
analyses.  All statistical analyses were conducted using IBM SPSS Statistics v 22, R 3.1.1 [https://
www.r-project.org/ ] and OpenEpi, version 3.01 
[https://www.openepi.com/Menu/OE_Menu.htm ].































































The number of gabapentin prescriptions in Scotland rose four-fold from 164,630 in 2006 to 694,293 in 
2016, with greater rises in the number of pregabalin prescriptions (Figure 1). In NHS Tayside gabapentin 
prescriptions numbered 16,481 in 2006 to 57,472 in 2016 (x3.5) and in NHS Fife, there were 20,465 
prescriptions issued in 2010, rising to 65,241 in 2016 (x3.2). Comparative rates in prescribing are shown 
in Figure 1.  
Sociodemographic characteristics 
In NHS Tayside and NHS Fife, 29,111 patients were prescribed a gabapentinoid in 2016, representing 
3.7% of the population of the two NHS Board areas. Of these, almost three quarters (73.2%, 
n=21,335) were recurrent users with 3 or more dispensed prescriptions (Table 1). The mean age of 
recurrent users was 58.1 years (SD 15.6), the highest proportion were women (62.5%) and they were 
more likely to live in areas of highest deprivation (SIMD quintile 5). The largest proportion of the 
recurrent users lived in urban areas (70.5%).
Co-prescribing of opioids and/or benzodiazepines
Co-prescribing was common, with almost 60% of those receiving gabapentinoids also prescribed an 
opioid and/or a benzodiazepine in 2016 (Table 2).  Similar rates of co-prescribing of opioids were seen 
among both males and females (50%) although there was significantly higher co-prescribing of 
benzodiazepines in females (28.5% vs 24.2%, p<0.05). The socio-demographic characteristics are shown 
in Tables 3 and 4. The mean age of the patients prescribed gabapentinoids along with opioids and/or 
benzodiazepines was 57.3 years (SD 15.8). Most of them were in the 41-60 years age group (p<0.01) 
and there was a higher proportion of women compared to men (63.6% vs. 36.4 %, p 
<0.0001). The majority of those receiving such a co-prescription resided in an urban area (70%, 
p=0.006), and they were more likely to live in the most deprived areas (p<0.001).  
Recurrent prescriptions of gabapentinoids were significantly associated with older age (age 41-60 years, 
OR 1.08 (95% CI 1.06 – 1.10) and living in more deprived areas (compared to SIMD 1 most deprived, 
SIMD 3, OR 0.94 (95%CI 0.92 – 0.95)) (Supplementary Table 2). 































































In total, there were 1,312 deaths in 2016 identified in the dataset (4.5% of those prescribed a 
gabapentinoid in 2016), with 54 of these (4.1%) classified as ‘drug-related deaths’. Compared with 
the Scottish general population the age standardised all-cause mortality was significantly higher in 
individuals prescribed gabapentinoids in NHS Tayside and Fife 2016: RR 2.16 (95% CI 2.08- 2.25, 
p<0.001) and for deaths due to respiratory disease (RR 1.32, 95% CI 1.15-1.50, p<0.001), although 
not for deaths due to circulatory disease (RR 1.03, 95% CI 0.91-1.41, p=0.64). (Supplementary Table 
3)
Drug-related deaths
There has been a steady increase in the number of drug-related deaths in Scotland and in NHS 
Tayside where gabapentin and pregabalin were implicated in or potentially contributed to the cause 
of death. (Figures 2a & 2b), although the percentages are higher in Tayside compared to the national 
rates for both drugs (gabapentin 23% vs 14%; pregabalin 33% vs 12% in 2017).  
In Tayside, gabapentin or pregabalin were implicated in the cause of death (as stated in post-
mortem cause of death) in 22 of 56 (39%) drug deaths in 2016. In 17 (77%) of these fatalities, the 
person had not been prescribed a gabapentinoid. In 2016, gabapentinoids were the third most 
common group of substances to be found in toxicology of drug deaths at post-mortem (39 
detections of pregabalin and/or gabapentin), after opioids and benzodiazepines."
People in whom a gabapentinoid was identified as contributing to the cause of drug death in Tayside 
in 2016 were slightly younger (mean age 37.2 years vs 40.2 years), more frequently male (82% vs 
76%), and a higher proportion were more likely to be living in areas of greater socioeconomic 
deprivation, although these differences were not statistically significant (Supplementary Table 4).  































































This study confirms the rapidly rising rate of gabapentinoid prescribing in Tayside and Fife, mirrored 
across Scotland. We found high rates of potentially dangerous co-prescribing of drugs that can interact 
with gabapentinoids, with 60% co-prescribed an opioid and/or a benzodiazepine (50% were co-
prescribed an opioid and 27% a benzodiazepine only). Factors associated with gabapentinoids 
prescribing and co-prescribing include older age, female gender and deprivation. Overall rates of DRDs 
in Scotland have increased,25 and DRDs where gabapentinoids are implicated or potentially 
contributed, has also increased as a proportion of all DRDs. This ‘contribution’ is found in 
approximately 26% of DRDs nationally and 47% in Tayside. This increase is at a similar rate to the 
increases in overall prescribing rates, implying that these may be connected. 
.
The completeness rate of the prescribing data, and community pharmacy dispensed prescriptions of 
gabapentinoids across Scotland (including NHS Tayside & Fife), is high.29 This produced a large and 
comprehensive study population, minimising selection bias and enabling analysis of some individual 
level socio-demographic characteristics. This is an advantage compared to studies that are restricted 
by prescription data from health insurance plans and claims data.33 However, data on individual 
characteristics were limited, which was necessary to maintain anonymity and minimise risk of 
potential disclosure of individual patients, resulting in mainly descriptive analysis and restricting the 
possibility of more complex statistical analyses. Furthermore, the prescribing data lacked clinical 
details and we were unable to associate gabapentinoid prescriptions with specific diagnoses including 
neuropathic pain or epilepsy. Also, although we were able to determine those patients who received a 
prescription for gabapentinoids and/or opioids and benzodiazepines in the same year, we are unable 
to confirm prescribing at the same time in the year.
Rising rates of gabapentinoids prescribing have been reported internationally.9-16, 34 35 Although these 
rates are generally comparable with our findings, these other studies report on different objectives, 






























































including a focus on treatment of neuropathic pain10,16, for epilepsy and non-epilepsy disorders 14-16,
restricted to only pregabalin prescribing13,16 and limited by data from a panel survey12 or public 
insurance data.13 
This paper focuses on all primary care gabapentinoids prescribing with detailed analysis of trends 
and associated socio-demographic characteristics and mortality with individual level data. The 
context of gabapentinoids use in Scotland is particularly important and distinctive given the highest 
rate of DRDs in Europe and the availability of detailed information from toxicology reports, 
contributing to a more complete picture of use and potential misuse.
In England, 3.3% of the population were prescribed gabapentinoids in one year (2017-2018) and 
12.8% were prescribed opioids.35 We found similar rates of gabapentinoid prescribing in Tayside 
(3.7%) and other research reported opioid analgesic prescribing rates at 11% in Tayside and a higher 
rate of 18% of the population in Scotland.11,37 The socio-demographic characteristics associated with 
gabapentinoid prescribing included age, with highest rates of prescribing found in 40-60 year olds, 
female gender and deprivation. Similar findings have also been reported for patients in England 35 
and these sociodemographic characteristics are also associated with reporting of chronic and 
neuropathic pain, and with opioid prescribing.37,38 Because gabapentin and opioids are both 
commonly prescribed for chronic pain, the likelihood of co-prescription is high.21,39 Other research 
has found 20% of all patients prescribed either gabapentin or pregabalin are also taking an opioid 9, 
whereas our data find a higher rate of co-prescribing of opioids at 50% of patients, and with 27% co-
prescribed a benzodiazepine. This is concerning as, on their own, prescribed gabapentinoids have 
been associated with an increased risk of suicidal behaviour, unintentional overdoses, head/body 
injuries, road traffic incidents and offences,24 and in combination with other medications, such as 
opioids or benzodiazepines, further increases in the risk of serious side-effects and overdose.9 37 39






























































Although initially presumed to have no abuse potential, a systematic review estimated the prevalence 
of gabapentin misuse in the general population to be 1%, 40–65% among individuals with 
prescriptions, and between 15% and 22% within populations of people who abuse opioids.21   
Gabapentinoids are misused primarily for recreational purposes, self-medication or intentional self-
harm and are misused alone or in combination with other substances, especially opioids, 
benzodiazepines and/or alcohol.22,24, 39,40
In a nested case-control study of opioid users, 8% of patients receiving opioids were co-prescribed 
gabapentin, and co-prescription was associated with a 50% increase in opioid-related death.40 In 
Scotland in 2010, gabapentin and/or pregabalin were implicated in, or potentially contributed to the 
cause of death in approximately 1% of all DRDs22 compared to data from 2018 25 where this figure 
rose to 13.7% of all DRDs. In Tayside this figure is even higher at 23% (although this may in part be due 
to differences in drug death definitions). DRDs include deaths that have occurred due to acute 
complications e.g. bronchopneumonia, however patients on prescribed opioids may not be identified 
as such, leading to the possibility of under-reporting. Aside from gender, where males are at higher 
risk, DRDs follow a similar sociodemographic pattern to gabapentin and opioids prescribing.37,38 
Prescribing rates were higher in females but DRDs, where gabapentinoids are implicated, were higher 
in males in Tayside, suggesting that drug diversion may be an issue. Overall, these findings support 
claims that prescribing is related to serious harms and/or have similar underlying causal factors. 
Drug-use disorders are the number one contributor to burden of disease in the most deprived areas of 
Scotland.26 Problematic drug use and DRDs are strongly associated with health inequality, as is 
gabapentinoid prescribing, and the prevalence of neuropathic pain.38 The average age of a person 
dying unintentionally as a result of illicit or illicitly acquired drug use in Tayside is currently 40.2 years. 
This compares to the national average age of death in Scotland of 81 years for females and 77 






























































years for males 41 and represents a gross health inequality in our population. The majority of drug 
deaths occur in people who have experienced considerable life adversity, often from a young age.  
Factors that influence risk are multi-dimensional, and problematic drug use is rarely an independent 
choice by an individual but the result of a complex interplay of social, economic and health factors.42 
The Public Health Minister for Scotland has said “What Scotland faces in terms of drug deaths is an 
emergency” and has consequently established a task force to promote action with the aim of 
improving health outcomes for people with problematic drug use.43
Whilst understanding the development of problematic drug use is more complicated than studying the 
specific substances involved, affordability and availability will impact on which substances are accessed 
by individuals. Currently, emerging trends show increases in the involvement of three key substance 
groups in drug-related deaths: atypical diazepams (principally etizolam), gabapentinoids and cocaine.25 
Each have different supply and distribution routes. Etizolam can be manufactured domestically and 
cocaine imported and both are illicit substances.  In contrast, gabapentinoids are prescribed 
medication and diversion of gabapentinoids appears to be an important risk factor in DRDs in Tayside, 
where toxicology reported the presence of these substances but further investigations found that they 
had not been prescribed to the vast majority of casualties.32 Other studies have confirmed toxicology 
reports without prescription or medical indication indicating that diversion is not uncommon.21,44 How 
the diversion of gabapentinoids occurs is uncertain and warrants further investigation.  
Conclusions
Prescribing of gabapentinoids has increased dramatically since 2006, as have the associated potential 
harms, dangerous co-prescribing and death (including DRDs). This study has important implications for 
preventive measures, aiming to reduce serious harms in the population. The public health emergency 
that has arisen from the increasing number of DRDs might be partly addressed by 






























































attention to gabapentinoid prescribing, but is also likely to require wider public health and political 
approaches to the common factors underlying the aetiology of chronic pain, substance misuse and 
DRDs.45
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Table 1. Characteristics of patients in NHS Tayside & Fife Health Board areas prescribed 
gabapentinoids in 2016 
Gabapentinoids users
(n=29,111)
Recurrent users (>3 
prescriptions) 
(n=21,335)
Total NHS Tayside and 
Fife Health Board area 
population
(n=785,800)
Age in years (mean, SD) 54.2 ± 14.2 58.12 ± 15.64 n/a
Age group (years), n (%)
0-20 99 (0.3) 58 (0.3) 174,194 (22.1)
21-40 4,230 (14.5) 2,888 (13.5) 192,263 (24.5)
41-60 12,109 (41.6) 9,133 (42.8) 216,421 (27.5)
61-80 10,149 (34.9) 7,400 (34.7) 163,957 (20.8)
80+ 2,524 (8.7) 1,856 (8.7) 38,965 (4.9)
Gender, n (%)
Female 18,231  (62.6) 13,334 (62.5) 404,085 (51.4)
Male 10,880 (37.4) 8,001 (37.5) 381,715 (48.6)
Health board, n (%)
Tayside 15,233 (52.3) 11,240 (52.7) 415,470 (52.9)
Fife 13,878 (47.7) 10,095 (47.3) 370,330 (47.1)
Deprivation Index (SIMD)*, n(%)
SIMD1 (most deprived) 6,907 (24.8) 5,358 (26.1) 143,157 (18.2)
SIMD2 6,344 (22.7) 4,796 (23.4) 139,032 (17.7)
SIMD3 5,438 (19.5) 3,893 (19) 159,478 (20.3)
SIMD4 5,893 (21.1) 4,156 (20.3) 192,578 (24.5)
SIMD5 (least deprived) 3,328 (11.9) 2,301 (11.2) 151,555 (19.3)
Rurality, n (%)
Combined Large Urban and Other 
Urban:
19,452 (69.7) 14,448 (70.5) 516,885 (65.8)
Accessible small town and remote 
small town combined
3,627 (13.0) 2,611 (12.7) 102,734 (13.1)
Accessible rural and remote rural 
combined
4,831 (17.3) 3,445 (16.8) 166,182 (21.1)
*SIMD = Scottish Index of Multiple Deprivation, % calculated for SIMD and Rurality on complete data






























































Table 2. Co-prescribing of opioids and/or benzodiazepines with gabapentinoids in NHS Tayside & 









Gabapentinoids + any opioids 14,574 (49.9) 5,442 (50.0) 9,132 (50.1) NS
Gabapentinoids + benzodiazepines 7,823 (26.8) 2,635 (24.2) 5,188 (28.5) <0.01
Gabapentinoids + opioids + 
benzodiazepines
4,986 (17.1) 1,732 (15.9) 3,254 (17.8) <0.01
Gabapentinoids + opioids and/or 
benzodiazepines




prescription records of opioids and/or 
benzodiazepines
11,700 (40.1) 4,535 (41.7) 7,165 (39.3) -
*% shown of co-prescribing within any gabapentinoid prescription
**% shown within male and female for co-prescribing
*** chi square test comparing % in males and females






























































Table 3. Socio-demographic characteristics of patients who received gabapentiniods prescriptions 








Age (mean, SD) 57.34±15.82 58.83±16.12 <0.0001
Age group, n(%)
0-20 37 (0.2) 62 (0.5) <0.01
21-40 2,681 (15.4) 1,549 (13.2)
41-60 7,497 (43.1) 4,612 (39.4)
61-80 5,743 (33.0) 4,406 (37.7)
80+ 1,453 (8.3) 1,071 (9.2)
Gender, n(%)
Female 11,066 (63.6) 7,165 (61.2) <0.0001
Male 6,345 (36.4) 4,535 (38.8)
Health board, n(%)
Tayside 9,392 (53.9) 5,631 (48.1) <0.0001
Fife 8,019 (46.1) 6,069 (51.9)
Deprivation Index (SIMD), n(%)
SIMD1 (most deprived) 4,447 (26.7) 2,460 (21.9) <0.00001
SIMD2 3,914 (23.5) 2,430 (21.6)
SIMD3 3,176 (19) 2,262 (20.1)
SIMD4 3,362 (20.2) 2,531 (22.5)
SIMD5 (least deprived) 1,763 (10.6) 1,565 (13.9)
Rurality code, n(%)




Accessible small town / remote 
small town combined 
2169 (13.0) 1458 (13.0)
Accessible rural / remote rural 
combined
2786 (16.7) 2045 (18.2)
*SIMD = Scottish Index of Multiple Deprivation.
Data are means ± standard deviation (SD) for continuous variables and counts (%) for categorical 
data. Univariate analysis was performed. P<0.05 taken as significant.































































Table 4. The association between socio-demographic factors and co-prescription of opioids and/or 





18-40 (2) Reference category
0-17 (1) 0.69 (0.57 - 0.82) <0.001
41-60 (3) 0.99 (0.98 - 1.01) 0.672
61-80 (4) 0.95 (0.93 - 0.96) <0.001
80+ (5) 0.96 (0.94 - 0.98) 0.004
Gender 
Female Reference category
Male 0.97 (0.96 - 0.98) <0.001
Deprivation Index (SIMD)
SIMD1 (most deprived) Reference category
SIMD2 0.97 (0.96 - 0.99) 0.0039
SIMD3 0.95 (0.93 - 0.96) <0.001
SIMD4 0.94 (0.92 - 0.95) <0.001
SIMD5 (least deprived) 0.90 (0.88 - 0.92) <0.001
* Multivariate logistic regression analysis 
SIMD = Scottish Index of Multiple Deprivation
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Figure 1.  Trends in prescribing of pregabalin and gabapentin in Scotland, NHS Tayside and NHS Fife (2006 to 2016) 
*Note: prescribing data for NHS Fife only available from 2010
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Figure 2a. Drug-related deaths where pregabalin and gabapentin were implicated in or potentially contributed to cause of death by number and 
percentage: Scotland 2012-2017¥
Footnote¥ Drug death, as defined by National Records of Scotland23
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Figure 2b. Drug deaths where pregabalin and gabapentin were implicated in or potentially contributed to cause of death by number and percentage: 
Tayside 2012-2017$
Footnote$ Drug death, as defined by the Tayside Drug Death Review Group31 (see text)





























































Supplementary table 1. Definition of drug related deaths 
Description ICD-10 codes 
Mental and behavioural disorders 
 Due to drug use (excluding alcohol and tobacco) 
 Unspecified cause/disorder 
 
F11- F16, F18-F19 
F99 
Accidental self-harm 
 Poisoning by drugs, medicaments and biological substances 
 Poisoning, other or unspecified exposure 






 Poisoning by drugs, medicaments and biological substances 
 Poisoning, other or unspecified exposure 






 Poisoning by drugs, medicaments and biological substances 
 Poisoning, other or unspecified exposure 





Self-harm, undetermined intent  
 Poisoning by drugs, medicaments and biological substances 
 Poisoning, other or unspecified exposure 






 Poisoning by drugs, medicaments and biological substances 
 Poisoning, other or unspecified exposure 











Supplementary table 2. The association between socio-demographic factors and recurrent use of gabapentinoids (>3 prescriptions) in NHS Tayside and 
Fife Health Board areas in 2016 
 
Estimated effect 
size S.E. P-value OR 




0.72 0.01 <2×10-16 2.03 1.71 2.37 
 0-17 (1) -0.14 0.08 0.07 0.86 0.74 1.02 
 41-60 (3) 0.08 0.01 <2×10-16 1.08 1.06 1.10 
 61-80 (4) 0.06 0.01 1.6×10-12 1.06 1.04 1.08 
 80+ (5) 0.07 0.01 1.1×10-10 1.07 1.05 1.10 
 18-40 (2) Reference category 
Gender        
 Male  0.002 0.005 0.632 1.00 0.99 1.01 
 Female  Reference category 
Deprivation Index (SIMD)       
 SIMD2 -0.02 0.01 0.007 0.97 0.96 0.99 
 SIMD3 -0.06 0.01 6.76×10-15 0.94 0.92 0.95 
 SIMD4 -0.07 0.01 <2×10-16 0.93 0.91 0.94 
 SIMD5 -0.08 0.01 <2×10-16 0.92 0.89 0.93 
 SIMD1 (most deprived) Reference category 
 
 
Supplementary Table 3. The comparison of age standardised mortality (per 100,000 persons) between Scotland and those prescribed a gabapentinoid at 
least once in NHS Tayside and Fife in 2016 








Relative risk  
(95% CI) 
P-value 
All-cause mortality  2454.1 1136.4 2.16 (2.08-2.25) <0.001 
Circulatory  313.9 305.9 1.03 (0.91-1.41) 0.64 





Supplementary Table 4.  Drug deaths in Tayside in 2016 by gabapentinoid involvement  
 Gabapentinoid implicated in 
cause of death 
(n=22) 
Gabapentinoid not implicated 
in cause of death  
(n= 34) 
Mean age (years) 37.2 40.2 
Male n (%) 18 (82) 26 (76) 
Deprivation Index (SIMD), n (%)   
   SIMD 1 (most deprived) 14 (64) 18 (53) 
   SIMD 2 5 (23) 8 (23) 
   SIMD 3 2 (9) 5 (15) 
   SIMD 4 1 (5) 3 (9) 
   SIMD 5 (least deprived) - - 
*Scottish Index of Multiple Deprivation (SIMD 
 
 
